Topic: infectious disease
Initial lab work suggests that the Ebola Zaire strain—the one targeted by Merck's rVSV-ZEBOV—is likely the cause of this outbreak.
Inovio's South Korean partner GeneOne plans to start a phase 1/2 study in South Korea in the third quarter.
GSK and Merck will still lead as the top vaccine makers in 2024, according to a new report, while Sanofi and Pfizer are expected to swap positions.
A new study showed Ocrevus could reduce patients' immune responses to vaccines against tetanus, seasonal flu and pneumococcus.
With MERS and Lassa fever projects funded, the outbreak-focused alliance is ready to put a check mark beside the third disease on its priority list.
The International AIDS Vaccine Initiative will use grant funding to develop a Lassa vaccine based on the VSV vector.
VBI-1501 showed neutralizing antibody activities against both fibroblast and epithelial cell infections.
The Pfizer men B shot grabs an approval-speeding designation just two months after GSK's Bexsero—Trumenba's archrival—got the same boost.
Here is some other vaccine news of note for the week.